<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1361" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1361/" /><meta name="ncbi_pagename" content="Lysinuric Protein Intolerance - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Lysinuric Protein Intolerance - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Lysinuric Protein Intolerance" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/04/12" /><meta name="citation_author" content="Virginia Nunes" /><meta name="citation_author" content="Harri Niinikoski" /><meta name="citation_pmid" content="20301535" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1361/" /><meta name="citation_keywords" content="Cationic Aminoaciduria" /><meta name="citation_keywords" content="Y+L amino acid transporter 1" /><meta name="citation_keywords" content="SLC7A7" /><meta name="citation_keywords" content="Lysinuric Protein Intolerance" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Lysinuric Protein Intolerance" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Virginia Nunes" /><meta name="DC.Contributor" content="Harri Niinikoski" /><meta name="DC.Date" content="2018/04/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1361/" /><meta name="description" content="Lysinuric protein intolerance (LPI) typically presents after an infant is weaned from breast milk or formula; variable findings include recurrent vomiting and episodes of diarrhea, episodes of stupor and coma after a protein-rich meal, poor feeding, aversion to protein-rich food, failure to thrive, hepatosplenomegaly, and muscular hypotonia. Over time, findings include: poor growth, osteoporosis, involvement of the lungs (progressive interstitial changes, pulmonary alveolar proteinosis) and of the kidneys (progressive glomerular and proximal tubular disease), hematologic abnormalities (normochromic or hypochromic anemia, leukopenia, thrombocytopenia, erythroblastophagocytosis in the bone marrow aspirate), and a clinical presentation resembling the hemophagocytic lymphohistiocytosis/macrophagic activation syndrome. Hypercholesterolemia, hypertriglyceridemia, and acute pancreatitis can also be seen." /><meta name="og:title" content="Lysinuric Protein Intolerance" /><meta name="og:type" content="book" /><meta name="og:description" content="Lysinuric protein intolerance (LPI) typically presents after an infant is weaned from breast milk or formula; variable findings include recurrent vomiting and episodes of diarrhea, episodes of stupor and coma after a protein-rich meal, poor feeding, aversion to protein-rich food, failure to thrive, hepatosplenomegaly, and muscular hypotonia. Over time, findings include: poor growth, osteoporosis, involvement of the lungs (progressive interstitial changes, pulmonary alveolar proteinosis) and of the kidneys (progressive glomerular and proximal tubular disease), hematologic abnormalities (normochromic or hypochromic anemia, leukopenia, thrombocytopenia, erythroblastophagocytosis in the bone marrow aspirate), and a clinical presentation resembling the hemophagocytic lymphohistiocytosis/macrophagic activation syndrome. Hypercholesterolemia, hypertriglyceridemia, and acute pancreatitis can also be seen." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1361/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/lpi/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1361/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CFCA0E04053C100000000091B034C.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1361_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1361_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hnpcc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/lal-def/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1361_"><span class="title" itemprop="name">Lysinuric Protein Intolerance</span></h1><p class="contrib-group"><span itemprop="author">Virginia Nunes</span>, PhD and <span itemprop="author">Harri Niinikoski</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1361_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1361_ai__"><div class="contrib half_rhythm"><span itemprop="author">Virginia Nunes</span>, PhD<div class="affiliation small">Professor of Genetics, Genetics Unit<br />Physiological Sciences <br />Faculty of Medicine &#x02013; Bellvitge Campus<br />University of Barcelona<br />Senior Investigator, Molecular Genetics Laboratory<br />Instituto de Investigaci&#x000f3;n Biom&#x000e9;dica de Bellvitge<br />Coordinator of the Genes Disease and Therapy Program at IDIBELL<br />Chief, Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Raras U730<br />Barcelona, Spain<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.bu@senunv" class="oemail">ude.bu@senunv</a><span style="unicode-bidi: bidi-override; direction: ltr;">; </span><a href="mailto:dev@null" data-email="tac.llebidi@senunv" class="oemail">tac.llebidi@senunv</a><div></div></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Harri Niinikoski</span>, MD, PhD<div class="affiliation small">Professor of Nutrition in Medicine<br />University of Turku<br />Pediatric Endocrinologist<br />Turku University Hospital<br />Turku, Finland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="if.skyt@iksokiniin.irrah" class="oemail">if.skyt@iksokiniin.irrah</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 21, 2006</span>; Last Update: <span itemprop="dateModified">April 12, 2018</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="lpi.Summary" itemprop="description"><h2 id="_lpi_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Lysinuric protein intolerance (LPI) typically presents after an infant is weaned from breast milk or formula; variable findings include recurrent vomiting and episodes of diarrhea, episodes of stupor and coma after a protein-rich meal, poor feeding, aversion to protein-rich food, failure to thrive, hepatosplenomegaly, and muscular hypotonia. Over time, findings include: poor growth, osteoporosis, involvement of the lungs (progressive interstitial changes, pulmonary alveolar proteinosis) and of the kidneys (progressive glomerular and proximal tubular disease), hematologic abnormalities (normochromic or hypochromic anemia, leukopenia, thrombocytopenia, erythroblastophagocytosis in the bone marrow aspirate), and a clinical presentation resembling the hemophagocytic lymphohistiocytosis/macrophagic activation syndrome. Hypercholesterolemia, hypertriglyceridemia, and acute pancreatitis can also be seen.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis is established in an individual with clinical and laboratory features suggestive of LPI including elevated 24-hour urinary excretion of cationic amino acids, especially lysine. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SLC7A7</i> pathogenic variants confirms the diagnosis.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> In acute hyperammonemic crises: intravenous administration of arginine chloride and nitrogen-scavenger drugs (sodium benzoate, sodium phenylacetate) to block ammonia production; reduction of excess nitrogen in the diet; provision of energy as carbohydrates to reduce catabolism. Long-term: dietary protein restriction; oral supplementation with citrulline and nitrogen-scavenger drugs, L-lysine-HCl, and carnitine; whole-lung lavage to improve respiratory function in persons with pulmonary alveolar proteinosis.</p><p><i>Prevention of primary manifestations:</i> Long-term protein restriction and administration of citrulline and nitrogen-scavenging drugs.</p><p><i>Prevention of secondary complications:</i> Minimize the risk of respiratory infections; vaccination against influenza is recommended. Varicella immunization in those without previous history of chickenpox or varicella zoster; treatment of those exposed as immune-compromised persons; revaccination may be required if poor response to polysaccharide-containing vaccines.</p><p><i>Surveillance:</i> Plasma concentration of amino acids to identify deficiencies of essential amino acids secondary to protein-restricted diet; fasting and postprandial blood ammonia concentrations and attention to signs of hyperammonemia, urinary orotic acid excretion; periodic evaluation of renal function; evaluation of lung involvement; periodic serum LDH and ferritin.</p><p><i>Agents/circumstances to avoid:</i> Large boluses of protein or amino acids.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to evaluate at-risk sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> or biochemical testing in order to reduce morbidity and mortality through early diagnosis and treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>LPI is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for a pregnancy at increased risk are possible using molecular genetic techniques if both pathogenic variants have been identified in an affected family member.</p></div></div><div id="lpi.Diagnosis"><h2 id="_lpi_Diagnosis_">Diagnosis</h2><div id="lpi.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Lysinuric protein intolerance (LPI) <b>should be suspected</b> in an infant who presents after weaning from breast milk or formula with the following features.</p><p><b>Early clinical features</b></p><ul><li class="half_rhythm"><div>Recurrent vomiting with episodes of diarrhea</div></li><li class="half_rhythm"><div>Episodes of stupor and coma after a protein-rich meal</div></li><li class="half_rhythm"><div>Poor feeding</div></li><li class="half_rhythm"><div>Aversion to protein-rich food</div></li><li class="half_rhythm"><div>Failure to thrive</div></li><li class="half_rhythm"><div>Enlargement of the liver and spleen</div></li><li class="half_rhythm"><div>Muscular hypotonia</div></li></ul><p><b>Later clinical features.</b> In some individuals, the diagnosis is established in adulthood. Over time, additional clinical features appear:</p><ul><li class="half_rhythm"><div>Poor growth</div></li><li class="half_rhythm"><div>Early (often severe) osteoporosis</div></li><li class="half_rhythm"><div>Subclinical or overt pulmonary involvement</div></li><li class="half_rhythm"><div>Renal involvement</div></li><li class="half_rhythm"><div>Hemophagocytic lymphohistiocytosis/macrophagic activation syndrome</div></li></ul><p><b>Biochemical laboratory features</b></p><ul><li class="half_rhythm"><div>Elevated plasma ammonia after a protein-rich meal. Fasting values are usually normal.</div></li><li class="half_rhythm"><div>Increased urinary orotic acid*</div></li><li class="half_rhythm"><div>Plasma amino acid concentrations:</div><ul><li class="half_rhythm"><div>Cationic amino acid (lysine, arginine, and ornithine) concentrations are usually below normal for age, but may be within the normal range.</div></li><li class="half_rhythm"><div>Serine, glycine, citrulline, proline, alanine, and glutamine concentrations are increased.</div></li></ul></li><li class="half_rhythm"><div>Urinary amino acid excretion. 24-hour urinary excretion of cationic amino acids, especially lysine, is increased.**</div></li></ul><p>*Note: (1) In some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, elevated urinary orotic acid excretion occurs in the absence of hyperammonemia. (2) Urinary orotic acid excretion may be within the normal range if an untreated person has had a prolonged fast or has excluded protein-rich food from the diet.</p><p>**Note: (1) In some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, calculation of the renal clearances of cationic amino acids (lysine, arginine, and ornithine) may be necessary to clarify the urinary loss of these amino acids. (2) Renal clearance of an amino acid is calculated using the same formula as for creatinine clearance, but substituting creatinine values with values of 24-hour urinary amino acid excretion and of the fasting plasma amino acid concentrations. (3) Mean values and ranges of the renal clearances of cationic amino acids in individuals with LPI were reported in <a class="bk_pop" href="#lpi.REF.simell.2001">Simell [2001]</a>. (4) Serine, glycine, citrulline, proline, alanine, and glutamine are found in excess in urine but have normal renal clearances.</p><p><b>Other laboratory features</b></p><ul><li class="half_rhythm"><div>Plasma concentrations of LDH, ferritin, and zinc are usually elevated.</div></li><li class="half_rhythm"><div>Normochromic or hypochromic anemia, leukopenia, and thrombocytopenia are nonspecific hematologic findings.</div></li><li class="half_rhythm"><div>Hypertriglyceridemia and hypercholesterolemia are frequently observed.</div></li></ul></div><div id="lpi.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of LPI <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above clinical and laboratory features. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC7A7</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> confirms the diagnosis (see <a class="figpopup" href="/books/NBK1361/table/lpi.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figlpiTmoleculargenetictestingusedin" rid-ob="figoblpiTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Individuals with the distinctive findings described in <a href="#lpi.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#lpi.Option_1">Option 1</a>), whereas those in whom the diagnosis of LPI has not been considered are more likely to be diagnosed using genomic testing (see <a href="#lpi.Option_2">Option 2</a>).</p><div id="lpi.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of LPI, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>SLC7A7</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div><div class="half_rhythm">Testing may begin with targeted analysis for the Finnish <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> <a class="figpopup" href="/books/NBK1361/table/lpi.T.selected_slc7a7_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figlpiTselectedslc7a7pathogenicvariant" rid-ob="figoblpiTselectedslc7a7pathogenicvariant">c.895-2A&#x0003e;T</a> in individuals of Finnish ancestry or for the founder variant <a class="figpopup" href="/books/NBK1361/table/lpi.T.selected_slc7a7_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figlpiTselectedslc7a7pathogenicvariant" rid-ob="figoblpiTselectedslc7a7pathogenicvariant">c.1228C&#x0003e;T</a> in individuals of Japanese ancestry. For individuals of other ancestry, targeted analysis for a known recurrent <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in those populations may be performed (see <a href="#lpi.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SLC7A7</i> and other genes of interest (see <a href="#lpi.Differential_Diagnosis">Differential Diagnosis</a>) may be considered to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1361/table/lpi.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figlpiTmoleculargenetictestingusedin" rid-ob="figoblpiTmoleculargenetictestingusedin">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="lpi.Option_2"><h4>Option 2</h4><p>When the diagnosis of LPI is not considered because an individual has atypical phenotypic features, comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. Exome sequencing is most commonly used; <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> is also possible. Exome array (when clinically available) may be considered if <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="lpi.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Lysinuric Protein Intolerance (LPI)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1361/table/lpi.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lpi.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC7A7</i></td><td headers="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">92%-95%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_lpi.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15%-20% in non-Finnish populations</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="lpi.TF.1.1"><p class="no_margin">See <a href="/books/NBK1361/#lpi.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="lpi.TF.1.2"><p class="no_margin">See <a href="#lpi.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="lpi.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="lpi.TF.1.4"><p class="no_margin">Presently, of around 400 alleles of persons in whom LPI is suspected, only around 5%-8% have not been characterized, giving a detection rate of approximately 92%-95%.</p></div></dd><dt>5. </dt><dd><div id="lpi.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="lpi.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#lpi.REF.sperandeo.2005.410">Sperandeo et al [2005]</a>, <a class="bk_pop" href="#lpi.REF.cimbalistiene.2007.277">Cimbalistiene et al [2007]</a>, <a class="bk_pop" href="#lpi.REF.sperandeo.2008.14">Sperandeo et al [2008]</a>, <a class="bk_pop" href="#lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al [2009]</a>, <a class="bk_pop" href="#lpi.REF.esseghir.2011.37">Esseghir et al [2011]</a></p></div></dd></dl></div></div></div></div></div></div><div id="lpi.Clinical_Characteristics"><h2 id="_lpi_Clinical_Characteristics_">Clinical Characteristics</h2><div id="lpi.Clinical_Description"><h3>Clinical Description</h3><p>Usually infants with lysinuric protein intolerance (LPI) present with gastrointestinal symptoms (feeding difficulties, vomiting, and diarrhea) soon after weaning from breast milk or formula.</p><p>Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants show failure to thrive early in life. Neurologic presentation with episodes of coma is less common. Moderate hepatosplenomegaly is present. Muscular hypotonia and hypotrophy are observed from early infancy. Poor growth and delayed skeletal maturation are common after the first year of life. Osteoporosis may result in pathologic fractures.</p><p>Intellectual development is usually normal unless episodes of prolonged coma cause neurologic damage.</p><p>Classic symptoms of protein intolerance may remain unnoticed during the first and second decades of life because of subconscious avoidance of dietary protein.</p><p>Treatment with a low-protein diet and supplementation with citrulline and nitrogen-scavenging drugs (see Management, <a href="#lpi.Treatment_of_Manifestations">Treatment of Manifestations</a>) significantly improve symptoms related to the metabolic abnormality. However, some complications, representing the major causes of morbidity and mortality, are not amenable to treatment.</p></div><div id="lpi.Complications"><h3>Complications</h3><p><b>Lung disease.</b> Progressive interstitial changes in the lung are frequently detected from early years without overt clinical symptoms. Progression to severe pulmonary alveolar proteinosis (PAP) is a well-known life-threatening complication, occurring as early as childhood in many individuals with LPI [<a class="bk_pop" href="#lpi.REF.valimahamedmitha.2015.257">Valimahamed-Mitha et al 2015</a>, <a class="bk_pop" href="#lpi.REF.mauhin.2017.3">Mauhin et al 2017</a>]. Pulmonary fibrosis may develop independently from PAP.</p><p>PAP usually presents with progressive exertional dyspnea, tachypnea, and cough that are exacerbated by respiratory infections and complicated by viral or bacterial pneumonia. Diminished breath sounds, inspiratory crackles, subcostal and suprasternal retractions, cyanosis, and, more rarely, digital clubbing can be found on physical examination.</p><p>Diffuse reticulonodular densities are common on radiologic evaluation. Chest high-resolution computed tomography reveals ground-glass opacities with superimposed smooth septal thickening.</p><p>The pathogenesis of the PAP in LPI is poorly understood, but may be associated with intracellular nitric oxide accumulation [<a class="bk_pop" href="#lpi.REF.mauhin.2017.3">Mauhin et al 2017</a>].</p><p><b>Renal involvement.</b> Glomerular and tubular involvement is common. Isolated mild proteinuria is the initial sign of renal disease leading to proximal tubular dysfunction and nephrocalcinosis [<a class="bk_pop" href="#lpi.REF.est_ve.2017.160">Est&#x000e8;ve et al 2017</a>, <a class="bk_pop" href="#lpi.REF.mauhin.2017.3">Mauhin et al 2017</a>]. Serum creatinine concentration and cystatin C concentration are frequently increased. In a study on 39 Finnish individuals with LPI, proteinuria and hematuria were observed in 74% and 38%, respectively. Elevated blood pressure, mild to moderate renal insufficiency, and, in some cases, end-stage renal disease were also reported in this cohort [<a class="bk_pop" href="#lpi.REF.tanner.2007">Tanner et al 2007</a>]. Urine beta2-microglobulin may serve as an early marker of renal involvement in LPI [<a class="bk_pop" href="#lpi.REF.k_rki.2016.47">K&#x000e4;rki et al 2016</a>].</p><p>Renal tubular acidosis or findings consistent with reduced phosphate reabsorption and generalized aminoaciduria indicate underlying complex proximal tubular disease (Fanconi syndrome).</p><p>Kidney histology reveals immune-mediated glomerulonephritis as well as chronic tubulointerstitial nephritis with glomerulosclerosis in the absence of immune deposits [<a class="bk_pop" href="#lpi.REF.est_ve.2017.160">Est&#x000e8;ve et al 2017</a>].</p><p>The pathogenesis of the renal involvement is unknown but may be associated with nitric oxide overproduction [<a class="bk_pop" href="#lpi.REF.nicolas.2016.11">Nicolas et al 2016</a>].</p><p><b>Hematologic complications and bone marrow anomalies.</b> A clinical presentation resembling hemophagocytic lymphohistiocytosis/macrophagic activation syndrome has been repeatedly observed.</p><p>Erythroblastophagocytosis and decreased megakaryocytes may be found in bone marrow aspirate. Hematologic findings also include slight normochromic or hypochromic anemia, leukopenia, thrombocytopenia, and subclinical intravascular coagulation.</p><p><b>Hypercholesterolemia and hypertriglyceridemia.</b> Increased plasma concentrations of cholesterol and triglycerides are relatively common in individuals with LPI [<a class="bk_pop" href="#lpi.REF.tanner.2010.s145">Tanner et al 2010</a>]. No clear explanation has been proposed for this dyslipidemic state; a higher-carbohydrate diet may contribute to the increased plasma concentration of triglycerides, but it is not sufficient to explain either the hypercholesterolemia or the severe hypertriglyceridemia (triglycerides &#x0003e;1,000 mg/dL or &#x0003e;11 mmol/L).</p><p><b>Autoimmunity and immunologic abnormalities.</b> Various immunologic abnormalities including impaired function of lymphocytes, the presence of lupus erythematosus cells, antinuclear and anti-DNA antibodies, hypergammaglobulinemia or low serum immune globulin concentrations, hypocomplementemia, and life-threatening varicella and bacterial infections can be observed.</p><p><b>Growth, growth hormone deficiency.</b> Growth retardation is commonly observed in children with LPI and is usually related to protein malnutrition. In some cases, growth hormone deficiency or arginine depletion causing impaired secretion of growth hormone is observed. Growth hormone has been used in several individuals with good response [<a class="bk_pop" href="#lpi.REF.niinikoski.2011.43">Niinikoski et al 2011</a>].</p><p><b>Pancreatitis.</b> Acute pancreatitis is a life-threatening complication in some persons with LPI. A clear relationship with severe hypertriglyceridemia has not been defined.</p><p><b>Pregnancy and childbirth.</b> A Finnish study demonstrated that maternal LPI is associated with increased risk of anemia and toxemia during pregnancy and increased risk of bleeding complications during delivery. Intrauterine growth retardation was noted in a significant number of unaffected neonates born to mothers with LPI [<a class="bk_pop" href="#lpi.REF.tanner.2006.224">Tanner et al 2006</a>].</p><p><b>Pathophysiology.</b> LPI is an inborn error of metabolism caused by pathogenic variants in <i>SLC7A7</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding the light chain of system y<sup>+</sup>L. This system mediates the transport of cationic amino acids at the basolateral membrane of enterocytes and renal tubular cells. Most of the clinical findings of LPI may be related to the metabolic abnormality originating from altered absorption and reabsorption of cationic amino acids. In this respect, hyperammonemia is caused by functional impairment of the urea cycle probably resulting from an intracellular deficiency of ornithine in the liver. However, nutritional imbalance of cationic amino acids does not explain the complex multiorgan involvement of LPI, especially the complications affecting lung, kidney, and immune and hematologic systems.</p><p>System y<sup>+</sup>L activity has been shown to be markedly reduced in monocytes and alveolar macrophages from an individual with LPI [<a class="bk_pop" href="#lpi.REF.barilli.2010.32">Barilli et al 2010</a>]. This could explain the pathogenesis of the severe complications of LPI including those affecting lung and kidney. A paradox may occur in LPI: on one hand, pathogenic variants in <i>SLC7A7</i> cause a general depletion of cationic amino acid secondary to defective intestinal uptake and renal reuptake; additionally, in immunocompetent cells the impairment of system y<sup>+</sup>L activity may cause intracellular arginine accumulation, with a potential risk of surcharging the nitric oxide pathway [<a class="bk_pop" href="#lpi.REF.sebastio.2011.54">Sebastio et al 2011</a>]. A lower dosage of citrulline supplementation is now recommended, given that citrulline is converted into arginine, notably in kidney.</p></div><div id="lpi.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations have not been found.</p><p>Variable expressivity is observed in individuals of Finnish origin who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the same <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>.</p><p>In a large Italian <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a>, homozygosity for <a class="figpopup" href="/books/NBK1361/table/lpi.T.selected_slc7a7_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figlpiTselectedslc7a7pathogenicvariant" rid-ob="figoblpiTselectedslc7a7pathogenicvariant">c.1381_1384dupATCA</a> gave rise to different clinical presentations: severe short stature with pancreatic and renal involvement in a girl; early pulmonary alveolar proteinosis causing death in a boy; a very mild clinical presentation in another boy whose brother had a similar clinical picture but died suddenly after a flu-like episode [<a class="bk_pop" href="#lpi.REF.sperandeo.2000.92">Sperandeo et al 2000</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1361/table/lpi.T.selected_slc7a7_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figlpiTselectedslc7a7pathogenicvariant" rid-ob="figoblpiTselectedslc7a7pathogenicvariant">c.726G&#x0003e;A</a> was found in 13 individuals belonging to nine independent families from Italy, Morocco, and North Africa. Five of the 13 had a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with pulmonary alveolar proteinosis [<a class="bk_pop" href="#lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</a>].</p><p>In 35 individuals with LPI of Japanese ancestry, no correlation between <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> and <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> was observed [<a class="bk_pop" href="#lpi.REF.noguchi.2016.979">Noguchi et al 2016</a>].</p></div><div id="lpi.Nomenclature"><h3>Nomenclature</h3><p>Lysinuric protein intolerance has also been referred to as cationic aminoaciduria.</p></div><div id="lpi.Prevalence"><h3>Prevalence</h3><p>More than 200 individuals with LPI have been reported; one third are of Finnish origin [<a class="bk_pop" href="#lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</a>, <a class="bk_pop" href="#lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</a>, <a class="bk_pop" href="#lpi.REF.carpentieri.2015.47">Carpentieri et al 2015</a>]. Isolated clusters of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have also been identified in southern Italy and Japan.</p><p>The disorder is found worldwide: individuals with LPI originate from at least 25 countries [<a class="bk_pop" href="#lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</a>, <a class="bk_pop" href="#lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</a>]. A <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> for specific alleles underlies the observed occurrence of LPI in Finland (<a class="figpopup" href="/books/NBK1361/table/lpi.T.selected_slc7a7_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figlpiTselectedslc7a7pathogenicvariant" rid-ob="figoblpiTselectedslc7a7pathogenicvariant">c.895-2A&#x0003e;T</a>) and in Japan (<a class="figpopup" href="/books/NBK1361/table/lpi.T.selected_slc7a7_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figlpiTselectedslc7a7pathogenicvariant" rid-ob="figoblpiTselectedslc7a7pathogenicvariant">c.1228C&#x0003e;T</a>). Surprisingly, the variant c.1228C&#x0003e;T was also found in a Moroccan individual [<a class="bk_pop" href="#lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</a>].</p><p>The incidence of LPI has been estimated at 1:60,000 newborns in Finland and 1:57,000 in Japan [<a class="bk_pop" href="#lpi.REF.koizumi.2000.270">Koizumi et al 2000</a>].</p></div></div><div id="lpi.Genetically_Related_Allelic_Disorder"><h2 id="_lpi_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>SLC7A7</i>.</p></div><div id="lpi.Differential_Diagnosis"><h2 id="_lpi_Differential_Diagnosis_">Differential Diagnosis</h2><p>The phenotypic variability of lysinuric protein intolerance (LPI) has resulted in various misdiagnoses.</p><p><b>Hyperammonemia.</b> Hyperammonemia and clinical manifestations related to it are shared by other metabolic diseases, notably the urea cycle disorders (see <a href="/books/n/gene/ucd-overview/">Urea Cycle Disorders Overview</a>). Increased orotic aciduria and hyperexcretion of cationic amino acids help to distinguish LPI from other hyperammonemic conditions.</p><p><b>Lysosomal storage diseases (LSDs).</b> Hepatosplenomegaly, interstitial lung disease, and hematologic manifestation may suggest LSDs.</p><p><b>Malabsorptive diseases.</b> The occurrence of gastrointestinal symptoms (e.g., vomiting, diarrhea) as well as of hypoproteinemia and failure to thrive suggests <a href="/books/n/gene/celiac/">celiac disease</a>. LPI should be included in the differential diagnosis of malabsorptive diseases.</p><p><b>Hemophagocytic lymphohistiocytosis/macrophagic activation syndrome.</b> Failure to thrive, hepatosplenomegaly, fever, hypertriglyceridemia, increased serum ferritin concentration, anemia, and other blood abnormalities suggest acquired or <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemophagocytic lymphohistiocytosis.</p><p><b>Autoimmune disorders.</b> Clinical and biochemical findings consistent with diagnosis of an autoimmune disorder such as systemic lupus erythematosus (SLE) were reported in individuals with LPI and, in some cases, were the presenting features.</p></div><div id="lpi.Management"><h2 id="_lpi_Management_">Management</h2><div id="lpi.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease in an individual diagnosed with lysinuric protein intolerance, the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>History for evidence of hyperammonemic crises with overt neurologic manifestations (vomiting, drowsiness, coma) and of respiratory involvement (cough, dyspnea, recurrent lower respiratory tract infections)</div></li><li class="half_rhythm"><div>Neurologic evaluation to detect secondary neurologic damage</div></li><li class="half_rhythm"><div>Respiratory evaluation including chest x-ray, pulmonary high-resolution computed tomography, and pulmonary function tests</div></li><li class="half_rhythm"><div>Evaluation and follow up of growth parameters</div></li><li class="half_rhythm"><div>Liver and spleen ultrasound examination to monitor liver structural changes and spleen enlargement</div></li><li class="half_rhythm"><div>Hematologic evaluation (bone marrow aspirate may be required)</div></li><li class="half_rhythm"><div>Immunologic assessment including plasma concentrations of immune globulins and, when clinically indicated, detection of autoimmune antibodies and immune complexes</div></li><li class="half_rhythm"><div>Renal function studies</div></li><li class="half_rhythm"><div>Bone density evaluation</div></li><li class="half_rhythm"><div>Consultation with a biochemical geneticist and/or genetic counselor</div></li></ul></div><div id="lpi.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The management of individuals with LPI is similar to that described in <a href="/books/n/gene/ucd-overview/">urea cycle disorders</a>. In LPI, the severity of hyperammonemic crises rarely requires extreme treatments such as dialysis and hemofiltration. It is recommended that individuals with LPI be cared for by a specialized metabolic team.</p><div id="lpi.Treatment_of_Acute_Hyperammonemic_Cr"><h4>Treatment of Acute Hyperammonemic Crises</h4><p><b>Pharmacologic management.</b> Blocking of ammonia production is accomplished by the intravenous administration of arginine chloride and of a combination of the nitrogen-scavenger drugs sodium phenylacetate and sodium benzoate. An intravenous loading dose is followed by an oral maintenance dose of nitrogen-scavenger drugs when the individual is stable. Depletion of branched chain amino acids (BCAAs) may occur as a consequence of the therapy with sodium phenylacetate [<a class="bk_pop" href="#lpi.REF.scaglia.2010.s72">Scaglia 2010</a>]. Persistence of BCAA deficiency hampers protein synthesis and induces catabolism. Therefore, careful evaluation of BCAA serum levels is recommended and specific supplementation may be required. Various detailed protocols for the treatment of intercurrent hyperammonemia in individuals with urea cycle disorders and (more generally) with hyperammonemia may be adopted [<a class="bk_pop" href="#lpi.REF.h_berle.2011.21">H&#x000e4;berle 2011</a>].</p><p><b>Reducing the amount of excess nitrogen in the diet and reducing catabolism through the introduction of energy supplied by carbohydrates and fat.</b> In acutely ill individuals, energy should be provided as carbohydrate and fat, either intravenously as glucose and Intralipid<sup>&#x000ae;</sup> or orally as protein-free formula.</p><p>Patients should be transitioned from parenteral to enteral feeds as soon as possible. Nasogastric tube feeding may be required to ensure adequate caloric and nutritional intake. Therapy with ondansetron can be started to decrease vomiting.</p><p>Complete restriction of protein for more than 24-48 hours is not recommended as the individual will become protein catabolic for essential amino acids.</p></div><div id="lpi.LongTerm_Treatment"><h4>Long-Term Treatment</h4><p><b>Dietary protein restriction and citrulline supplementation.</b> Current treatment consists of dietary protein restriction (0.8-1.5 g/kg/day in children and 0.5-0.8 g/kg/day in adults) and supplementation with citrulline (&#x02264;100 mg/kg/day, in 4 doses taken with meals). Nitrogen-scavenger drugs such as sodium benzoate (100-250 mg/kg/day in 4 divided doses) should be added to keep the lowest effective dosage of citrulline. As in the management of other inherited metabolic disorders, diet must be tailored on the basis of individual tolerance for the protein charge and carefully monitored to avoid disturbances of both growth and nutritional status.</p><p>Measurement of orotic aciduria appears to be a sensitive tool for adjustment of treatment.</p><p><b>Lysine supplementation.</b> As lysine deficiency may contribute to the development of pathologic signs in LPI, oral supplementation with L-lysine-HCl should be attempted. Taking into account the defective intestinal absorption of lysine in LPI, small doses of L-lysine-HCl (20-30 mg/kg/day, in 3-4 doses per day) are given and may normalize plasma lysine concentrations [<a class="bk_pop" href="#lpi.REF.tanner.2007">Tanner et al 2007</a>].</p><p><b>Carnitine supplementation.</b> In a survey of 37 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of Finnish ancestry, hypocarnitemia was found to be associated with female sex, renal insufficiency, and the use of ammonia-scavenging drugs. When documented, hypocarnitemia should be corrected (25-50 mg/kg/day) [<a class="bk_pop" href="#lpi.REF.tanner.2008.549">Tanner et al 2008</a>].</p><p><b>Additional therapies.</b> In individuals with dyslipidemia, diet modification and fish oil supplementation should be tried before initiating pharmacologic treatment.</p></div><div id="lpi.Treatment_of_Late_Complications"><h4>Treatment of Late Complications</h4><p>While hyperammonemia can be efficiently prevented and treated, no effective therapy has been established for late complications.</p><p><b>Treatment of lung disease</b> in LPI remains controversial: high-dose corticosteroid treatment was effective in a few patients when started early, whereas no response was noted in others.</p><p>In individuals with pulmonary alveolar proteinosis (PAP), treatment with granulocyte/monocyte colony-stimulating factor (GM-CSF) was shown to be ineffective or even to worsen the clinical course [<a class="bk_pop" href="#lpi.REF.santamaria.2004.268">Santamaria et al 2004</a>]. However, in a Finnish study GM-CSF appeared to benefit two individuals with severe PAP [<a class="bk_pop" href="#lpi.REF.tanner.2010.s145">Tanner et al 2010</a>]. Increased GM-CSF and decreased bioavailability of surfactant protein D have been proposed as a part of the mechanism underlying PAP in LPI [<a class="bk_pop" href="#lpi.REF.douda.2009.29">Douda et al 2009</a>]. Whole-lung lavage remains the best therapeutic approach for PAP in LPI [<a class="bk_pop" href="#lpi.REF.ceruti.2007.14">Ceruti et al 2007</a>]; however, relapses may require serial lavage.</p><p>Heart-lung transplantation was attempted with a temporary successful result, but it did not prevent a fatal return of the lung disease [<a class="bk_pop" href="#lpi.REF.santamaria.2004.268">Santamaria et al 2004</a>].</p><p>Bone marrow transplantation has been discussed as a possible treatment for PAP in LPI. The rationale of this therapeutic approach would rely on the hypothesis of a defective function of lung macrophages [<a class="bk_pop" href="#lpi.REF.barilli.2010.32">Barilli et al 2010</a>, <a class="bk_pop" href="#lpi.REF.sebastio.2011.54">Sebastio et al 2011</a>].</p><p><b>Treatment of renal disease</b> in LPI should follow the standard guidelines under direction of the nephrologist.</p><p><b>Treatment of hemophagocytic lymphohistiocytosis / macrophagic activation syndrome</b> in LPI should be formulated under the direction of a specialist.</p></div></div><div id="lpi.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>The prevention of metabolic abnormality is the goal of treatment. Long-term management is based on protein-restricted diet and administration of citrulline (see <a href="#lpi.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p></div><div id="lpi.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>The onset and the clinical course of the secondary complications (e.g., lung and renal involvement) appear to be poorly responsive to early treatment.</p><p>Efforts to minimize the risk of respiratory infections should be promoted. Vaccination against influenza (and possibly pneumococci) is recommended.</p><p>An individual with LPI without previous history of chickenpox or varicella zoster should be vaccinated or, if exposed to varicella, treated as an immune-compromised person.</p><p>Some individuals with LPI may respond poorly to polysaccharide-containing vaccines. Therefore, revaccination may be required if specific antibody titers are non-protective.</p></div><div id="lpi.Surveillance"><h3>Surveillance</h3><p>Individuals with LPI should be referred for follow up to physicians with expertise in the treatment of inborn errors of metabolism. The age of the patient and the severity of the clinical features determine the frequency of clinical visits and monitoring.</p><p>Monitoring should include the following:</p><ul><li class="half_rhythm"><div>Plasma concentrations of amino acids to identify deficiencies of essential amino acids induced by the protein-restricted diet (similar to that used in <a href="/books/n/gene/ucd-overview/">urea cycle disorders</a>)</div></li><li class="half_rhythm"><div>Attention to early signs of hyperammonemia including lethargy, nausea, vomiting, and poor feeding in young children, and headache and mood changes in older children</div></li><li class="half_rhythm"><div>Fasting and postprandial blood ammonia concentrations</div></li><li class="half_rhythm"><div>Urinary orotic acid excretion</div></li><li class="half_rhythm"><div>Evaluation of renal function</div></li><li class="half_rhythm"><div>Attention to early clinical signs of lung involvement</div></li><li class="half_rhythm"><div>Serum concentrations of LDH and ferritin</div></li></ul><p>The development of a multiorgan pathology in LPI requires careful surveillance of several complications including lung and renal diseases and osteoporosis. No specific guidelines have been proposed. Therefore, a tailored approach is necessary for the follow up of a specific complication.</p></div><div id="lpi.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Large boluses of protein or amino acids should be avoided.</p><p>It is not clear whether prolonged fasting may trigger hyperammonemic crises.</p></div><div id="lpi.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate at-risk sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> in order to reduce morbidity and mortality through early diagnosis and treatment:</p><ul><li class="half_rhythm"><div>If the pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk sibs should be performed. Plasma and urine amino acid and urinary orotic acid analyses are recommended in individuals with suspected LPI while awaiting molecular genetic results.</div></li><li class="half_rhythm"><div>If the pathogenic variants in the family are not known, early diagnosis of at-risk sibs relies on detailed clinical evaluation and determination of plasma and urinary amino acid concentrations and orotic acid urinary excretion.</div></li></ul><p>See <a href="#lpi.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="lpi.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy management should be performed in a center familiar with metabolic diseases. Frequent plasma amino acid and ammonia measurements are recommended as well as overall well-being of the mother and fetus. Most infants with LPI are born prematurely (between gestational weeks 31 and 39) [<a class="bk_pop" href="#lpi.REF.tanner.2006.224">Tanner et al 2006</a>]. Pregnant women with LPI are at risk of toxemia and bleeding complications during and after delivery.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="lpi.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div><div id="lpi.Other"><h3>Other</h3><p>No treatment, including strict compliance with dietary regimen, citrulline supplementation, or high-dose corticosteroids, is effective in influencing the clinical course of the renal disease.</p></div></div><div id="lpi.Genetic_Counseling"><h2 id="_lpi_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="lpi.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Lysinuric protein intolerance (LPI) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="lpi.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>SLC7A7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with LPI are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SLC7A7</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>SLC7A7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="lpi.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p><b>Molecular genetic <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a></b> for at-risk relatives requires prior identification of the <i>SLC7A7</i> pathogenic variants in the family.</p><p><b>Note:</b> Biochemical testing (e.g., plasma concentration of amino acids or urinary excretion of orotic acid) cannot distinguish carriers from controls.</p></div><div id="lpi.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#lpi.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="lpi.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the <i>SLC7A7</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Biochemical testing</b> cannot currently be used to distinguish between <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and unaffected fetuses.</p></div></div><div id="lpi.Resources"><h2 id="_lpi_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Urea Cycle Disorders Foundation</b></div><div>75 South Grand Avenue</div><div>Pasadena CA 91105</div><div><b>Phone:</b> 800-386-8233 (toll-free); 626-578-0833</div><div><b>Fax:</b> 626-578-0823</div><div><b>Email:</b> info@nucdf.org</div><div><a href="http://www.nucdf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nucdf.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD)</b></div><div><a href="https://www.e-imd.org/event/european-registry-and-network-intoxication-type-metabolic-diseases" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.e-imd.org/en/index.phtml</a></div></li><li class="half_rhythm"><div><b>Urea Cycle Disorder International Patient Registry</b></div><div><b>Phone:</b> 626-578-0833</div><div><b>Fax:</b> 626-578-0823</div><div><b>Email:</b> coordinator@ucdparegistry.org</div><div><a href="https://ucdparegistry.patientcrossroads.org/index.php?option=com_content&#x00026;view=article&#x00026;id=412&#x00026;Itemid=484" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ucdregistry.org</a></div></li><li class="half_rhythm"><div><b>Urea Cycle Disorders Consortium Registry</b></div><div>Children's National Medical Center</div><div><b>Phone:</b> 202-306-6489</div><div><b>Email:</b> jseminar@childrensnational.org</div><div><a href="https://www.rarediseasesnetwork.org/cms/ucdc/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rarediseasesnetwork.org/cms/ucdc/</a></div></li></ul></div><div id="lpi.Molecular_Genetics"><h2 id="_lpi_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="lpi.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Lysinuric Protein Intolerance: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1361/table/lpi.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lpi.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_lpi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_lpi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_lpi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_lpi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_lpi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_lpi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_lpi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/9056" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SLC7A7</i></a></td><td headers="hd_b_lpi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=9056" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">14q11<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_lpi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UM01" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Y+L amino acid transporter 1</a></td><td headers="hd_b_lpi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/SLC7A7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC7A7 @ LOVD</a></td><td headers="hd_b_lpi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC7A7" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC7A7</a></td><td headers="hd_b_lpi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC7A7[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC7A7</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="lpi.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="lpi.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Lysinuric Protein Intolerance (<a href="/omim/222700,603593" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1361/table/lpi.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lpi.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/222700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">222700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LYSINURIC PROTEIN INTOLERANCE; LPI</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603593" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603593</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOLUTE CARRIER FAMILY 7 (CATIONIC AMINO ACID TRANSPORTER, y+ SYSTEM), MEMBER 7; SLC7A7</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>SLC7A7</i> has ten exons and 11 introns and spans 46.5 kbp in length on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 14. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1361/#lpi.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> To date, about 60 <i>SLC7A7</i> pathogenic variants have been identified as causative of lysinuric protein intolerance (LPI) [<a class="bk_pop" href="#lpi.REF.borsani.1999.297">Borsani et al 1999</a>, <a class="bk_pop" href="#lpi.REF.torrents.1999.293">Torrents et al 1999</a>, <a class="bk_pop" href="#lpi.REF.shoji.2002.375">Shoji et al 2002</a>, <a class="bk_pop" href="#lpi.REF.sperandeo.2008.14">Sperandeo et al 2008</a>, <a class="bk_pop" href="#lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</a>, <a class="bk_pop" href="#lpi.REF.carpentieri.2015.47">Carpentieri et al 2015</a>]. Most pathogenic variants reported in these studies are <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a>, except for the Finnish <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> c.895-2A&#x0003e;T, found in 38 individuals; the variant c.726G&#x0003e;A, found in 13; and c.1228C&#x0003e;T, the most frequent <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the Japanese population [<a class="bk_pop" href="#lpi.REF.noguchi.2016.979">Noguchi et al 2016</a>] (and also found in an individual of Moroccan origin [<a class="bk_pop" href="#lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s et al 2009</a>]).</p><p>All types of pathogenic variants have been observed: <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants account for 54.4% and 28.6%, respectively; deletions, insertions, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants, and large <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> rearrangements together account for 3.6%) (<a href="http://varsome.com/gene/SLC7A9" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varsome.com/gene/SLC7A9</a>).</p><div id="lpi.T.selected_slc7a7_pathogenic_variant" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>SLC7A7</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1361/table/lpi.T.selected_slc7a7_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__lpi.T.selected_slc7a7_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.726G&#x0003e;A&#x000a0;<sup>2</sup></td><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp242Ter</td><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_003982.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003982<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_003973.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003973<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.895-2A&#x0003e;T&#x000a0;<sup>3</sup><br />(1181-2A&#x0003e;T or 1136-2A&#x0003e;T)</td><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1228C&#x0003e;T</td><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg410Ter</td></tr><tr><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1381_1384dupATCA<br />(1670insATCA or 1384_1385insATCA)</td><td headers="hd_h_lpi.T.selected_slc7a7_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg462AsnfsTer7</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="lpi.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="lpi.TF.2.2"><p class="no_margin">Described in Italian and North African individuals; see <a href="#lpi.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></dd><dt>3. </dt><dd><div id="lpi.TF.2.3"><p class="no_margin">Founder variant of Finnish population; previously reported as 1181-2A&#x0003e;T by <a class="bk_pop" href="#lpi.REF.torrents.1999.293">Torrents et al [1999]</a> and as 1136-2A&#x0003e;T by <a class="bk_pop" href="#lpi.REF.borsani.1999.297">Borsani et al [1999]</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>SLC7A7</i> encodes the Y<sup>+</sup>L amino acid transporter 1 (y<sup>+</sup>LAT-1) protein; y<sup>+</sup>LAT-1 is linked by a disulfide bond to solute carrier family 3 member 2 (SLC3A2, also known as 4F2hc), which represents the heavy chain subunit of the heterodimeric amino acid transporter defective in LPI. This transporter, located at the basolateral membrane of epithelial cells, induces a system y<sup>+</sup>L activity.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Expression studies in cell culture systems demonstrated that the tested <i>SLC7A7</i> pathogenic variants are functionally different from wild type and that most abolish y<sup>+</sup>L activity [<a class="bk_pop" href="#lpi.REF.mykk_nen.2000.431">Mykk&#x000e4;nen et al 2000</a>, <a class="bk_pop" href="#lpi.REF.sperandeo.2005.410">Sperandeo et al 2005</a>].</p></div><div id="lpi.References"><h2 id="_lpi_References_">References</h2><div id="lpi.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.barilli.2010.32">Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Kadija Z, Rodi G, Mariani F, Ruzza ML, Luisetti M, Dall'Asta V. In lysinuric protein intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2010;<span class="ref-vol">5</span>:32.</span> [<a href="/pmc/articles/PMC2999609/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2999609</span></a>] [<a href="/pubmed/21110863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21110863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.borsani.1999.297">Borsani G, Bassi MT, Sperandeo MP, De Grandi A, Buoninconti A, Riboni M, Manzoni M, Incerti B, Pepe A, Andria G, Ballabio A, Sebastio G. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. <span><span class="ref-journal">Nat Genet. </span>1999;<span class="ref-vol">21</span>:297–301.</span> [<a href="/pubmed/10080183" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10080183</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.carpentieri.2015.47">Carpentieri D, Barnhart MF, Aleck K, Miloh T, deMello D. Lysinuric protein intolerance in a family of Mexican ancestry with a novel SLC7A7 gene deletion. Case report and review of the literature. <span><span class="ref-journal">Mol Genet Metab Rep. </span>2015;<span class="ref-vol">2</span>:47–50.</span> [<a href="/pmc/articles/PMC5471162/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5471162</span></a>] [<a href="/pubmed/28649527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28649527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.ceruti.2007.14">Ceruti M, Rodi G, Stella GM, Adami A, Bolongaro A, Baritussio A, Pozzi E, Luisetti M. Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2007;<span class="ref-vol">2</span>:14.</span> [<a href="/pmc/articles/PMC1845139/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1845139</span></a>] [<a href="/pubmed/17386098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17386098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.cimbalistiene.2007.277">Cimbalistiene L, Lehnert W, Huoponen K, Kucinskas V. First reported case of lysinuric protein intolerance (LPI) in Lithuania, confirmed biochemically and by DNA analysis. <span><span class="ref-journal">J Appl Genet. </span>2007;<span class="ref-vol">48</span>:277–80.</span> [<a href="/pubmed/17666782" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17666782</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.douda.2009.29">Douda DN, Farmakovski N, Dell S, Grasemann H, Palaniyar N. SP-D counteracts GM-CSF-mediated increase of granuloma formation by alveolar macrophages in lysinuric protein intolerance. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2009;<span class="ref-vol">4</span>:29.</span> [<a href="/pmc/articles/PMC2807424/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2807424</span></a>] [<a href="/pubmed/20030831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20030831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.esseghir.2011.37">Esseghir N, Bouchlaka CS, Fredj SH, Chehida AB, Azzouz H, Fontaine M, Tebib N, Dridi MF, Briand G, Messaoud T, Elgaaied AB, Kaabachi N. First report of a molecular prenatal diagnosis in a Tunisian family with lysinuric protein intolerance. <span><span class="ref-journal">JIMD Rep. </span>2011;<span class="ref-vol">1</span>:37–8.</span> [<a href="/pmc/articles/PMC3509814/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3509814</span></a>] [<a href="/pubmed/23430825" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430825</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.est_ve.2017.160">Est&#x000e8;ve E, Krug P, Hummel A, Arnoux JB, Boyer O, Brassier A, de Lonlay P, Vuiblet V, Gobin S, Salomon R, Pietrement C, Bonnefont JP, Servais A, Galmiche L. Renal involvement in lysinuric protein intolerance: contribution of pathology to assessment of heterogeneity of renal lesions. <span><span class="ref-journal">Hum Pathol. </span>2017;<span class="ref-vol">62</span>:160–9.</span> [<a href="/pubmed/28087478" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28087478</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.fontllitj_s.2009.71">Font-Llitj&#x000f3;s M, Rodriguez-Santiago B, Espino M, Sillue R, Manas S, Gomez L, Perez-Jurado LA, Palacin M, Nunes V. Novel SLC7A7 large rearrangements in lysinuric protein intolerance patients involving the same AluY repeat. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:71–9.</span> [<a href="/pmc/articles/PMC2985956/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2985956</span></a>] [<a href="/pubmed/18716612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18716612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.h_berle.2011.21">H&#x000e4;berle J. Clinical practice: the management of hyperammonemia. <span><span class="ref-journal">Eur J Pediatr. </span>2011;<span class="ref-vol">170</span>:21–34.</span> [<a href="/pubmed/21165747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21165747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.k_rki.2016.47">K&#x000e4;rki M, Nanto-Salonen K, Niinikoski H, Tanner LM. Urine beta2-microglobulin is an early marker of renal involvement in LPI. <span><span class="ref-journal">JIMD Rep. </span>2016;<span class="ref-vol">25</span>:47–55.</span> [<a href="/pmc/articles/PMC5059186/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5059186</span></a>] [<a href="/pubmed/26122628" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26122628</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.koizumi.2000.270">Koizumi A, Shoji Y, Nozaki J, Noguchi A. E X, Dakeishi M, Ohura T, Tsuyoshi K, Yasuhiko W, Manabe M, Takasago Y, Takada G. A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect. The Mass Screening Group. <span><span class="ref-journal">Hum Mutat. </span>2000;<span class="ref-vol">16</span>:270–1.</span> [<a href="/pubmed/10980538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10980538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.mauhin.2017.3">Mauhin W, Habarou F, Gobin S, Servais A, Brassier A, Grisel C, Roda C, Pinto G, Moshous D, Ghalim F, Krug P, Deltour N, Pontoizeau C, Dubois S, Assoun M, Galmiche L, Bonnefont JP, Ottolenghi C, de Blic J, Arnoux JB, de Lonlay P. Update on lysinuric protein intolerance, a multi-faceted disease retrospective cohort analysis from birth to adulthood. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2017;<span class="ref-vol">12</span>:3.</span> [<a href="/pmc/articles/PMC5217205/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5217205</span></a>] [<a href="/pubmed/28057010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28057010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.mykk_nen.2000.431">Mykk&#x000e4;nen J, Torrents D, Pineda M, Camps M, Yoldi ME, Horelli-Kuitunen N, Huoponen K, Heinonen M, Oksanen J, Simell O, Savontaus ML, Zorzano A, Palacin M, Aula P. Functional analysis of novel mutations in y(+)LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI). <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:431–8.</span> [<a href="/pubmed/10655553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10655553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.nicolas.2016.11">Nicolas C, Bednarek N, Vuiblet V, Boyer O, Brassier A, De Lonlay P, Galmiche L, Krug P, Baudouin V, Pichard S, Schiff M, Pietrement C. Renal involvement in a French paediatric cohort of patients with lysinuric protein intolerance. <span><span class="ref-journal">JIMD Rep. </span>2016;<span class="ref-vol">29</span>:11–7.</span> [<a href="/pmc/articles/PMC5059217/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5059217</span></a>] [<a href="/pubmed/26608393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26608393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.niinikoski.2011.43">Niinikoski H, Lapatto R, Nuutinen M, Tanner L, Simell O, Nanto-Salonen K. Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance. <span><span class="ref-journal">JIMD Rep. </span>2011;<span class="ref-vol">1</span>:43–7.</span> [<a href="/pmc/articles/PMC3509816/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3509816</span></a>] [<a href="/pubmed/23430827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430827</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.noguchi.2016.979">Noguchi A, Nakamura K, Murayama K, Yamamoto S, Komatsu H, Kizu R, Takayanagi M, Okuyama T, Endo F, Takasago Y, Shoji Y, Takahashi T. Clinical and genetic features of lysinuric protein intolerance in Japan. <span><span class="ref-journal">Pediatr Int. </span>2016;<span class="ref-vol">58</span>:979–83.</span> [<a href="/pubmed/26865117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26865117</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.santamaria.2004.268">Santamaria F, Brancaccio G, Parenti G, Francalanci P, Squitieri C, Sebastio G, Dionisi-Vici C, D'Argenio P, Andria G, Parisi F. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. <span><span class="ref-journal">J Pediatr. </span>2004;<span class="ref-vol">145</span>:268–72.</span> [<a href="/pubmed/15289783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15289783</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.scaglia.2010.s72">Scaglia F. New insights in nutritional management and amino acid supplementation in urea cycle disorders. <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">100</span> Suppl 1:S72–6.</span> [<a href="/pmc/articles/PMC4831209/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4831209</span></a>] [<a href="/pubmed/20299258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20299258</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.sebastio.2011.54">Sebastio G, Sperandeo MP, Andria G. Lysinuric protein intolerance: reviewing concepts on a multisystem disease. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2011;<span class="ref-vol">157C</span>:54–62.</span> [<a href="/pubmed/21308987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21308987</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.shoji.2002.375">Shoji Y, Noguchi A, Shoji Y, Matsumori M, Takasago Y, Takayanagi M, Yoshida Y, Ihara K, Hara T, Yamaguchi S, Yoshino M, Kaji M, Yamamoto S, Nakai A, Koizumi A, Hokezu Y, Nagamatsu K, Mikami H, Kitajima I, Takada G. Five novel SLC7A7 variants and y+L gene-expression pattern in cultured lymphoblasts from Japanese patients with lysinuric protein intolerance. <span><span class="ref-journal">Hum Mutat. </span>2002;<span class="ref-vol">20</span>:375–81.</span> [<a href="/pubmed/12402335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12402335</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.simell.2001">Simell O. Lysinuric protein intolerance and other cationic aminoacidurias. In: Scriver C, Beaudet A, Sly W, Valle D, and Vogelstein B. <em>The Metabolic and Molecular Basis of Inherited Disease.</em> Vol 4. 8 ed. New York, NY: McGraw-Hill; 2001:4933-56.</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.sperandeo.2008.14">Sperandeo MP, Andria G, Sebastio G. Lysinuric protein intolerance: update and extended mutation analysis of the SLC7A7 gene. <span><span class="ref-journal">Hum Mutat. </span>2008;<span class="ref-vol">29</span>:14–21.</span> [<a href="/pubmed/17764084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17764084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.sperandeo.2005.410">Sperandeo MP, Annunziata P, Ammendola V, Fiorito V, Pepe A, Soldovieri MV, Taglialatela M, Andria G, Sebastio G. Lysinuric protein intolerance: identification and functional analysis of mutations of the SLC7A7 gene. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:410.</span> [<a href="/pubmed/15776427" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15776427</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.sperandeo.2000.92">Sperandeo MP, Bassi MT, Riboni M, Parenti G, Buoninconti A, Manzoni M, Incerti B, Larocca MR, Di Rocco M, Strisciuglio P, Dianzani I, Parini R, Candito M, Endo F, Ballabio A, Andria G, Sebastio G, Borsani G. Structure of the SLC7A7 gene and mutational analysis of patients affected by lysinuric protein intolerance. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">66</span>:92–9.</span> [<a href="/pmc/articles/PMC1288352/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288352</span></a>] [<a href="/pubmed/10631139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10631139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.tanner.2006.224">Tanner L, Nanto-Salonen K, Niinikoski H, Erkkola R, Huoponen K, Simell O. Hazards associated with pregnancies and deliveries in lysinuric protein intolerance. <span><span class="ref-journal">Metabolism. </span>2006;<span class="ref-vol">55</span>:224–31.</span> [<a href="/pubmed/16423630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16423630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.tanner.2007">Tanner LM, Nanto-Salonen K, Niinikoski H, Jahnukainen T, Keskinen P, Saha H, Kananen K, Helantera A, Metso M, Linnanvuo M, Huoponen K, Simell O. Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance. J Pediatr 2007;150:631-4, 634 e1. [<a href="/pubmed/17517249" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17517249</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.tanner.2008.549">Tanner LM, Nanto-Salonen K, Rashed MS, Kotilainen S, Aalto M, Venetoklis J, Niinikoski H, Huoponen K, Simell O. Carnitine deficiency and L-carnitine supplementation in lysinuric protein intolerance. <span><span class="ref-journal">Metabolism. </span>2008;<span class="ref-vol">57</span>:549–54.</span> [<a href="/pubmed/18328359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18328359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.tanner.2010.s145">Tanner LM, Niinikoski H, Nanto-Salonen K, Simell O. Combined hyperlipidemia in patients with lysinuric protein intolerance. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span> Suppl 3:S145–50.</span> [<a href="/pubmed/20177788" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20177788</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.torrents.1999.293">Torrents D, Mykk&#x000e4;nen J, Pineda M, Feliubadalo L, Estevez R, de Cid R, Sanjurjo P, Zorzano A, Nunes V, Huoponen K, Reinikainen A, Simell O, Savontaus ML, Aula P, Palacin M. Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. <span><span class="ref-journal">Nat Genet. </span>1999;<span class="ref-vol">21</span>:293–6.</span> [<a href="/pubmed/10080182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10080182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.valimahamedmitha.2015.257">Valimahamed-Mitha S, Berteloot L, Ducoin H, Ottolenghi C, de Lonlay P, de Blic J. Lung involvement in children with lysinuric protein intolerance. <span><span class="ref-journal">J Inherit Metab Dis. </span>2015;<span class="ref-vol">38</span>:257–63.</span> [<a href="/pubmed/25335805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25335805</span></a>]</div></li></ul></div><div id="lpi.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.br_er.2017.1935">Br&#x000f6;er S, Br&#x000f6;er A. Amino acid homeostasis and signaling in mammalian cells and organism. <span><span class="ref-journal">Biochem J. </span>2017;<span class="ref-vol">474</span>:1935–63.</span> [<a href="/pmc/articles/PMC5444488/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5444488</span></a>] [<a href="/pubmed/28546457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28546457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.br_er.2011.193">Br&#x000f6;er S, Palacin M. The role of amino acid transporters in inherited and acquired diseases. <span><span class="ref-journal">Biochem J. </span>2011;<span class="ref-vol">436</span>:193–211.</span> [<a href="/pubmed/21568940" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21568940</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="lpi.REF.morris.2016.2579s">Morris SM Jr. Arginine metabolism revisited. <span><span class="ref-journal">J Nutr. </span>2016;<span class="ref-vol">146</span>:2579S–86S.</span> [<a href="/pubmed/27934648" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27934648</span></a>]</div></li></ul></div></div><div id="lpi.Chapter_Notes"><h2 id="_lpi_Chapter_Notes_">Chapter Notes</h2><div id="lpi.Acknowledgments"><h3>Acknowledgments</h3><p>Spanish Health Institute Carlos III Grants: FIS PI13/00121-R-FEDER and PI16/00267-R-FEDER (to V.N.), Generalitat de Catalunya Grants SGR2009-1490 (to V.N.)</p></div><div id="lpi.Author_History"><h3>Author History</h3><p>Simona Fecarotta, MD; Federico II University (2006-2011)<br />Harri Niinikoski, MD, PhD (2018-present)<br />Virginia Nunes, PhD (2011-present)<br />Gianfranco Sebastio, MD; Federico Il University (2006-2018)<br />Maria Pia Sperandeo, PhD; Federico Il University (2006-2011)</p></div><div id="lpi.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 April 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 October 2011 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/targeted-mutation-analysis/">targeted mutation analysis</a> for the c.895-2A&#x0003e;T founder mutation available clinically</div></li><li class="half_rhythm"><div>31 May 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 December 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>22 September 2006 (gs) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1361</span><span class="label">PMID: <a href="/pubmed/20301535" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301535</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hnpcc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/lal-def/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1361&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1361/?report=reader">PubReader</a></li><li><a href="/books/NBK1361/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1361" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1361" style="display:none" title="Cite this Page"><div class="bk_tt">Nunes V, Niinikoski H. Lysinuric Protein Intolerance. 2006 Dec 21 [Updated 2018 Apr 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1361/pdf/Bookshelf_NBK1361.pdf">PDF version of this page</a> (437K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#lpi.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#lpi.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#lpi.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#lpi.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#lpi.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#lpi.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#lpi.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#lpi.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#lpi.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#lpi.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#lpi.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=9056[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC7A7</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1497458" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1497458" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1497458" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1497458" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22649802" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Camacho J, Rioseco-Camacho N. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22593918" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Propionic Acidemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Shchelochkov OA, Carrillo N, Venditti C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301360" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrin Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrin Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Saheki T, Song YZ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21290785" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Argininosuccinate Lyase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Argininosuccinate Lyase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nagamani SCS, Erez A, Lee B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301631" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrullinemia Type I</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Citrullinemia Type I<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Quinonez SC, Thoene JG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301535" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301535" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041afcdd21425a257684aa">Lysinuric Protein Intolerance - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Lysinuric Protein Intolerance - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:29:16-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CFCA0E04053C100000000091B034C&amp;ncbi_session=CE8CFCA0E041AFC1_2331SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1361%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1361&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1361/&amp;ncbi_pagename=Lysinuric Protein Intolerance - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CFCA0E041AFC1_2331SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>